Select Your Location:

Tislelizumab in 2L treatment of advanced or metastatic ESCC

Watch this video to understand the mode of action of Chimeric Degradation Activating Compounds (CDAC), a new investigational targeted approach for hematologic malignancies.

BGB-16673 is an investigational chimeric degradation activating compound (CDAC) targeting BTK. Watch the mechanism of action video (MoA) to learn more.